COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.
Jian-Hua LiuJu-Ze LinQianhui QiuChangbin ZhuWeiwei LiQian LiZhan HuangXueer XiaGuibin QiaoJiming TangPublished in: Thoracic cancer (2023)
The findings of this study provide insight into the optimal design of individual treatments for ESCC patients.